--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-265835" form_type: "8-K" ticker: "PRLD" cik: "0001678660" company_name: "Prelude Therapeutics Inc" filed_at: "2026-06-10T20:11:13+00:00" generated_at: "2026-06-10T20:18:27.005997+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.25 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Prelude Therapeutics annual meeting: all director nominees elected, auditor ratified, say-on-pay approved ## Summary - Elected Krishna Vaddi, Paul Scherer, Katina Dorton as Class III directors with over 26.9M shares for each. - Ratified Ernst & Young LLP as independent auditor for FY2026 with 31,841,080 shares for, 4,951 against. - Advisory vote to approve 2025 named executive officer compensation passed with 26,869,142 shares for. - Stockholders selected '1 Year' as frequency for future say-on-pay votes with 26,877,941 votes. ## SEC filing metadata - accession: 0001193125-26-265835 - form_type: 8-K - ticker: PRLD - cik: 0001678660 - company_name: Prelude Therapeutics Inc - filed_at: 2026-06-10T20:11:13+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.25 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/prld-20260609.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-265835 - JSON: https://secwatch.observer/filing/0001193125-26-265835.json - Plain text: https://secwatch.observer/filing/0001193125-26-265835.txt ## Key facts - Shareholder Votes Prelude Therapeutics Inc shareholders approved Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlie at the 2026-06-09 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-09 source text: On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders: 1. Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal, based on the following votes: Nominees Shares For Shares Withheld Broker Non-Votes Krishna Vaddi, Ph.D. 26,996,820 55,937 4,799,016 Paul Scherer, MD, Ph.D. 25,532,267 1,520,490 4,799,016 Katina Dorton, J.D., MBA 26,998,601 54,156 4,799,016 evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm - Shareholder Votes Prelude Therapeutics Inc shareholders approved Advisory vote to approve the 2025 compensation for the Company's named executive officers at the 2026-06-09 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-09 source text: 3. Advisory vote to approve the 2025 compensation for the Company's named executive officers, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 26,869,142 107,500 76,115 4,799,016 evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm - Shareholder Votes Prelude Therapeutics Inc shareholders approved Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers at the 2026-06-09 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2026-06-09 source text: 4. Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers, based on the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 26,877,941 65,638 103,237 5,941 4,799,016 evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm - Shareholder Votes Prelude Therapeutics Inc shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-09 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-09 source text: 2. Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 31,841,080 4,951 5,742 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.